Updated Partner Group Picture 2015

  • Robert A. Ingram

    General Partner

    Bob's picture 11-12-15

    Mr. Robert Ingram, also known as Bob, is a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies. Prior to joining Hatteras, Mr. Ingram was Chief Executive Officer and Chairman of Glaxo/Wellcome. Mr. Ingram co-led the merger and integration that formed GlaxoSmithKline. Upon reaching mandatory retirement age of 60, Mr. Ingram served as the Vice Chairman, Pharmaceuticals at GSK before becoming Strategic Advisor to the CEO of GlaxoSmithKline Plc. Mr. Ingram is Chairman of the boards of Novan, Inc., a late-stage pharmaceutical company focused on dermatology, and Viamet Pharmaceuticals Inc., a private company focused on anti-infective research. He also serves as the Lead Director on the board of Cree, Inc. and is a member of the Board of Directors of Valeant Pharmaceuticals International, and BioCryst Pharmaceuticals, Inc. In 2013, Bob received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors.

    At the request of US President George H.W. Bush, Bob formed and chaired the CEO Roundtable on Cancer. In 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. In 2014, Bob received the North Carolina Award, the highest civilian honor the state can bestow on an individual. He received the award for public service. He serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GlaxoSmithKline Foundation.

    Bob is a member of numerous other civic and professional organizations, including the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, CEO Roundtable on Cancer, and the Advisory Council of the Congressional Task Force on Biomedical Research and Innovation.

    Bob graduated from Eastern Illinois University with a BS degree in Business Administration.

    Community and Board Engagements:

    Bob is a member of numerous other civic and professional organizations, including the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, CEO Roundtable on Cancer, and the Advisory Council of the Congressional Task Force on Biomedical Research and Innovation.

  • Christy Shaffer, PhD

    General Partner

    Christy Shaffer, PhD

    Seasoned entrepreneur and biotech executive, Christy Shaffer, Ph.D. has over 25 years of experience in the life science industry. Following her career as a clinical scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co., she joined Inspire Pharmaceuticals in 1995 as the first, full-time employee. She was responsible for raising over $300m for the company, including taking the company public in 2000. As President and CEO, Christy grew the company from 20 scientists to nearly 250 employees with revenues of over $100 million. Under her leadership, Inspire was named as “Best Place to Work for Scientists” by the Scientist magazine, and “Best Place to Work in North Carolina.” Christy retired from Inspire in 2010 and the company was acquired by Merck in 2011. She joined Hatteras in 2011 as the Managing Director of Hatteras Discovery and became a general partner in 2016.

    Christy serves as a board member of seven Hatteras portfolio companies and chairs five of them: Artizan Biosciences (Chair), Clearside Biomedical (Chair), GrayBug Vision (Chair), Trefoil Therapeutics (Chair), G1 Therapeutics, and Spyryx. Christy is a receptor pharmacologist by training, earning her Ph.D. in Pharmacology from the University of Tennessee Health Science Center, Memphis TN in 1985. She received her post-doctoral training at The Chicago Medical School and the University of North Carolina at Chapel Hill.

    Community and Board Engagements:

    Christy played an integral role in the Chancellor’s Innovation Circle to enhance entrepreneurship and innovation across the UNC-Chapel Hill campus (2010 – 2012). She has served on numerous boards including the NC Biotechnology Center, the Biotechnology Institute, BIO, PhRMA and the Cystic Fibrosis Foundation. Christy received the Breath of Life Award for the Cystic Fibrosis Foundation in 2009 and the Hamner Leadership Award at the NC BIOTECH meeting in 2011. TiE Atlanta awarded Christy the 2013 Venture Capital Entrepreneur Award at the TieCON Southeast conference.

    She received the Lifetime Women in Business Award by the Triangle Business Journal in 2016 and was named one of the top BizWomen to Watch in December, 2016. Christy currently serves on several non-profit boards including the Chordoma Foundation, the Council for Entrepreneurial Development, the NC School of Science and Mathematics Foundation board, the Burroughs Wellcome Regulatory Initiative Advisory board, the Morehead Planetarium and Science Center Advisory board and the Frank Hawkins Kenan’s Institute’s Advisory Board.

  • Clay B. Thorp

    General Partner

    Clay B. Thorp

    Clay is an entrepreneur turned venture capitalist. Since 1995, Clay has co-founded eight companies in the life science arena and co-founded Hatteras in 2000. Since co-founding Hatteras, Clay has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $450 million across five venture funds. Clay has led investments in a range of life science companies, including biopharmaceutical, medical device, diagnostics, and research informatics.

    Clay has led investments and numerous strategic transaction processes in a variety of portfolio companies, including PhaseBio, ArtusLabs, Clearside Biomedical, Synthematix, Embrella, Asthmatx, Lysosomal Therapeutics, Inc., and others. In operating roles, Clay was a co-founder and served as CEO and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired in April 2005 by Symyx Technologies (SMMX). He was the co-founder and head of corporate development for Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio for $106.7 million in May of 2000. Prior to Novalon, Clay was the co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins.

    Clay currently serves as Executive Chairman of PhaseBio Pharmaceuticals and Chairman of GeneCentric Diagnostics. He is also on the boards of Clearside Biomedical (Nasdaq: CLSD), Curoverse, Lysosomal Therapeutics, Artizan Biosciences and Orig3n. In 2014, Clay served as Co-Chair of the Innovation-2-Jobs Working Group for the Governor of the state of North Carolina. He serves on the Board of Visitors of the Lineberger Comprehensive Cancer Center at the University of North Carolina and on the board of the NC School of Science and Mathematics Foundation. He holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and art history from the University of North Carolina at Chapel Hill.

    Community and Board Engagements:

    Clay started his career as a social entrepreneur by co-founding the Student Coalition for Action in Literacy Education (SCALE) as a junior at UNC-Chapel Hill in 1989. For that, he was honored as Point of Light by President George H.W. Bush. Since that time, Clay has been active at state and national levels in public policy and public service. He is a past board member of the NC Biotechnology Center, CED, Public Allies, and the Wildacres Leadership Initiative. He serves on the Board of Visitors of the Lineberger Comprehensive Cancer Center at the University of North Carolina and on the board of the Foundation of the NC School of Science and Mathematics.

  • Douglas Reed, MD

    General Partner

    Douglas Reed
    Doug joined Hatteras Venture Partners as a General Partner in 2007. He has over 20 years of venture investment experience between Hatteras and two prior healthcare-focused venture firms, Vector Fund Management and S.R. One. He has also spent part of his career in operating roles as VP of Business Development for two biotechnology companies, NPS Pharmaceuticals (acquired by Shire) and GelTex Pharmaceuticals (acquired by Genzyme). Doug focuses on investments in the bio-pharmaceutical and medical technology fields. He currently serves as Chairman of the Board of Innocrin Pharmaceuticals and is also a director of BlinkBio, Contego Medical, NeuroTronik, Ltd., and Viamet Pharmaceuticals. He was a director of Embrella Cardiovascular prior to its sale to Edwards Lifesciences.

    Doug earned a BA in biology and an MD from the University of Missouri – Kansas City. He completed a residency in diagnostic radiology at the University of Washington and a fellowship in neuro-radiology at the University of British Columbia. He held faculty positions in the Department of Radiology at the University of Washington and at Yale University. He also obtained an MBA in Finance from the Wharton School at the University of Pennsylvania.

    Community and Board Engagements:

    Doug serves on the board of the Southeastern Biotechnology Organization (SEBIO) and on the National Board of Visitors of his alma mater the University of Missouri – Kansas City School of Medicine.

  • John Crumpler

    General Partner

    John Crumpler

    John co-founded Hatteras in 2000 after a successful career as a technology entrepreneur. At Hatteras, John is responsible for the firm’s investments in healthcare and life science information technology, and overall fund operations. He was founder and CEO of E-Comm, Inc., a software development and services firm specializing in remote and mobile computing that was acquired by XcelleNet. John ran the services division of XcelleNet until the company was acquired by Sterling Commerce.

    John served on the boards of Synthematix and Clinverse, and currently serves on the boards of Medfusion, Jumo Health, Wildflower Health, Bivarus and Clinipace Worldwide. At Clinipace John has helped lead the transformation of Clinipace from a pure software company to a full-service digital CRO. He holds an A.B. from Harvard University.

    Community and Board Engagements:

    Throughout his career John has been active in government and public policy at the state and federal levels. A recipient of the Lyndhurst Prize, John served on the N. C. Economic Development Board, the state’s Clean Water Management Trust Fund board of directors, and as a trustee of the University of North Carolina School of the Arts. He currently serves on the board of the Council for Entrepreneurial Development and as a director of SouthLight, Inc.

  • Kenneth B. Lee, Jr.

    General Partner

    Kenneth B. Lee

    Kenneth B. Lee, Jr. is involved in deal sourcing, investment decisions and implementing exit strategies as a general partner of HVP III. He is also a general partner for HVP II, where he has played an important role in deal sourcing, syndication and management recruitment, and evaluation. Ken is the former co-head of International Life Sciences for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world.

    He got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the firm’s national life sciences practice from his location in the San Francisco Bay Area, he advised numerous high profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. Among others, these included: Affymax, Affymetrix, Applied ImmuneSciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA, and Collagen.

    Ken serves on the Board of Directors of Clinverse, and is Chairman of the Board of Clinipace. He graduated with a BA from Lenoir-Rhyne College and has an MBA from the University of North Carolina at Chapel Hill.

    Community and Board Engagements:

    Ken is a nationally-recognized financial matters expert and serves on the boards of Maxygen, Inc. (MAXY), Pozen, Inc. (POZN) and Biocryst. He was formerly Chairman of the Board of Inspire Pharmaceuticals, Inc. (ISPH), prior to the sale of the company. Until April 2009, Ken was also on the board of CV Therapeutics, which was acquired by Gilead Sciences, Inc.